Latest Breaking News On - Stefanie molkenthin - Page 1 : comparemela.com

Boehringer Ingelheim s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Press release content from Business Wire. The AP news staff was not involved in its creation.

Rheinland pfalzUnited statesSan franciscoCarinne brouillonStefanie molkenthinLuca richeldiCorporate communicationsBoehringer ingelheimDrug administrationInternational conference breaking newsAmerican thoracic societyNew england journalRespiratory medicineCattolica del sacro cuorePrincipal investigatorManaging directors

Boehringer Ingelheim s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Boehringer Ingelheim s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Rheinland pfalzUnited statesSan franciscoCarinne brouillonStefanie molkenthinLuca richeldiCorporate communicationsBoehringer ingelheimDrug administrationInternational conference breaking newsAmerican thoracic societyNew england journalRespiratory medicineCattolica del sacro cuorePrincipal investigatorManaging directors

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced today.1

Rheinland pfalzStephan thalenStefan ankerWaheed jamalStefanie molkenthinEli lillyJeff emmickProduct developmentEuropean medicines agencyBoehringer ingelheimCommittee for medicinal products human usePreserved phaseMedicinal productsHuman useProfessor stefan ankerHeart failure cardiologist

Boehringer Ingelheim: CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction

- The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40%1 If

Stephan thalenStefan ankerWaheed jamalStefanie molkenthinEli lillyJeff emmickProduct developmentEuropean medicines agencyBoehringer ingelheimCommittee for medicinal products human usePreserved phaseMedicinal productsHuman useProfessor stefan ankerHeart failure cardiologistPreserved principal

Boehringer Ingelheim: Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status

In a new sub-analysis of the landmark EMPEROR-Preserved Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney

United statesStephan thalenFaiez zannadWaheed jamalStefanie molkenthinEli lillyJeff emmickGlobal business communicationsBoehringer ingelheimLilly allianceProgram clinical investigatorProduct developmentEuropean unionUniversity of lorraineAmerican society of nephrology kidney weekAmerican society